First Wave Biopharma Has Achieved Enrollment Target In Its Phase 2 SPAN Trial Of An Enhanced Enteric Microgranule Delivery Formulation Of Adrulipase For Exocrine Pancreatic Insufficiency In Cystic Fibrosis Patients; Top Line Data On Track For July 2023
Portfolio Pulse from Benzinga Newsdesk
First Wave Biopharma has reached its enrollment target for the Phase 2 SPAN trial of Adrulipase, an enhanced enteric microgranule delivery formulation for exocrine pancreatic insufficiency in cystic fibrosis patients. Top line data is expected in July 2023.
June 13, 2023 | 11:04 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
First Wave Biopharma's achievement of enrollment target for Phase 2 SPAN trial of Adrulipase may positively impact its stock price.
First Wave Biopharma's achievement of the enrollment target for the Phase 2 SPAN trial of Adrulipase indicates progress in the development of the drug. This milestone may be seen as a positive sign by investors, potentially leading to an increase in the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100